(CENT) Central Garden & Pet - Overview
Stock: Pet Accessories, Aquatic Supplies, Garden Seeds, Fertilizers, Wild-Bird Feed
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 34.5% |
| Relative Tail Risk | -14.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -8.35 |
| Character TTM | |
|---|---|
| Beta | 0.583 |
| Beta Downside | 0.298 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.77% |
| CAGR/Max DD | 0.11 |
Description: CENT Central Garden & Pet January 13, 2026
Central Garden & Pet Company (NASDAQ:CENT) designs, manufactures, and distributes a broad portfolio of lawn-and-garden and pet-care products across the United States, operating through two distinct segments: Pet and Garden.
The Pet segment, which accounts for roughly 70 % of total revenue, offers dog and cat treats, toys, bedding, grooming supplies, waste-management products, as well as specialty items for aquatics, small animals, reptiles, birds, equine, and livestock. Core brands include Aqueon, Kaytee, K&H Pet Products, Nylabone, and Zilla.
The Garden segment, contributing about 30 % of revenue, supplies grass and vegetable seed, flower and herb packets, bird feed and accessories, fertilizers, decorative items, live plants, and a range of herbicides, insecticides, and pesticides under the Amdro, Ferry-Morse, Pennington, and Sevin names.
Products reach consumers via independent distributors, big-box retailers, national and regional chains, e-commerce platforms, grocery stores, nurseries, and mass-merchant outlets, with e-commerce now representing roughly 15 % of sales and growing at double-digit rates year-over-year.
Key performance indicators from the most recent fiscal year show total net sales of approximately $2.1 billion, a pet-segment gross margin of 42 % versus 35 % for garden, and an operating cash flow conversion of 85 %. The business is sensitive to discretionary-spending trends, raw-material cost inflation (particularly for fertilizers and pet-food ingredients), and the ongoing “human-of-the-pet” premiumization wave that has driven a 12 % CAGR in pet treat volumes over the past three years.
For a deeper, data-driven valuation, you might explore ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income: 155.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -2.27 > 1.0 |
| NWC/Revenue: 45.04% < 20% (prev 41.71%; Δ 3.33% < -1%) |
| CFO/TA 0.09 > 3% & CFO 331.1m > Net Income 155.7m |
| Net Debt (886.0m) to EBITDA (341.9m): 2.59 < 3 |
| Current Ratio: 3.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.1m) vs 12m ago -5.17% < -2% |
| Gross Margin: 32.11% > 18% (prev 0.30%; Δ 3182 % > 0.5%) |
| Asset Turnover: 86.08% > 50% (prev 91.13%; Δ -5.05% > 0%) |
| Interest Coverage Ratio: 4.47 > 6 (EBITDA TTM 341.9m / Interest Expense TTM 57.7m) |
Altman Z'' 4.40
| A: 0.38 (Total Current Assets 1.97b - Total Current Liabilities 574.0m) / Total Assets 3.64b |
| B: 0.28 (Retained Earnings 1.01b / Total Assets 3.64b) |
| C: 0.07 (EBIT TTM 258.3m / Avg Total Assets 3.59b) |
| D: 0.49 (Book Value of Equity 1.01b / Total Liabilities 2.07b) |
| Altman-Z'' Score: 4.40 = AA |
Beneish M -3.23
| DSRI: 0.93 (Receivables 357.8m/399.4m, Revenue 3.09b/3.22b) |
| GMI: 0.92 (GM 32.11% / 29.56%) |
| AQI: 1.00 (AQ_t 0.31 / AQ_t-1 0.31) |
| SGI: 0.96 (Revenue 3.09b / 3.22b) |
| TATA: -0.05 (NI 155.7m - CFO 331.1m) / TA 3.64b) |
| Beneish M-Score: -3.23 (Cap -4..+1) = AA |
What is the price of CENT shares?
Over the past week, the price has changed by +10.18%, over one month by +17.33%, over three months by +19.62% and over the past year by -1.20%.
Is CENT a buy, sell or hold?
- StrongBuy: 3
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CENT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 46.5 | 22.4% |
| Analysts Target Price | 46.5 | 22.4% |
| ValueRay Target Price | 37.7 | -0.7% |
CENT Fundamental Data Overview February 09, 2026
P/E Forward = 12.87
P/S = 0.7655
P/B = 1.5015
P/EG = 2.56
Revenue TTM = 3.09b USD
EBIT TTM = 258.3m USD
EBITDA TTM = 341.9m USD
Long Term Debt = 1.19b USD (from longTermDebt, last quarter)
Short Term Debt = 52.9m USD (from shortTermDebt, last quarter)
Debt = 1.61b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 886.0m USD (from netDebt column, last quarter)
Enterprise Value = 3.25b USD (2.37b + Debt 1.61b - CCE 721.1m)
Interest Coverage Ratio = 4.47 (Ebit TTM 258.3m / Interest Expense TTM 57.7m)
EV/FCF = 11.41x (Enterprise Value 3.25b / FCF TTM 285.0m)
FCF Yield = 8.76% (FCF TTM 285.0m / Enterprise Value 3.25b)
FCF Margin = 9.22% (FCF TTM 285.0m / Revenue TTM 3.09b)
Net Margin = 5.04% (Net Income TTM 155.7m / Revenue TTM 3.09b)
Gross Margin = 32.11% ((Revenue TTM 3.09b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 30.87% (prev 28.98%)
Tobins Q-Ratio = 0.89 (Enterprise Value 3.25b / Total Assets 3.64b)
Interest Expense / Debt = 0.90% (Interest Expense 14.5m / Debt 1.61b)
Taxrate = 23.39% (2.09m / 8.93m)
NOPAT = 197.9m (EBIT 258.3m * (1 - 23.39%))
Current Ratio = 3.42 (Total Current Assets 1.97b / Total Current Liabilities 574.0m)
Debt / Equity = 1.02 (Debt 1.61b / totalStockholderEquity, last quarter 1.58b)
Debt / EBITDA = 2.59 (Net Debt 886.0m / EBITDA 341.9m)
Debt / FCF = 3.11 (Net Debt 886.0m / FCF TTM 285.0m)
Total Stockholder Equity = 1.57b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.34% (Net Income 155.7m / Total Assets 3.64b)
RoE = 9.90% (Net Income TTM 155.7m / Total Stockholder Equity 1.57b)
RoCE = 9.34% (EBIT 258.3m / Capital Employed (Equity 1.57b + L.T.Debt 1.19b))
RoIC = 7.16% (NOPAT 197.9m / Invested Capital 2.76b)
WACC = 5.08% (E(2.37b)/V(3.97b) * Re(8.06%) + D(1.61b)/V(3.97b) * Rd(0.90%) * (1-Tc(0.23)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 7.78%
[DCF Debug] Terminal Value 85.48% ; FCFF base≈313.7m ; Y1≈289.2m ; Y5≈260.3m
Fair Price DCF = 720.7 (EV 7.84b - Net Debt 886.0m = Equity 6.95b / Shares 9.65m; r=5.90% [WACC]; 5y FCF grow -9.81% → 2.90% )
EPS Correlation: -17.20 | EPS CAGR: -38.12% | SUE: 0.87 | # QB: 1
Revenue Correlation: -32.83 | Revenue CAGR: -10.97% | SUE: -0.47 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.09 | Chg30d=-0.011 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=2.83 | Chg30d=+0.038 | Revisions Net=-1 | Growth EPS=+3.5% | Growth Revenue=-0.1%
EPS next Year (2027-09-30): EPS=2.97 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+5.1% | Growth Revenue=+2.1%